A search for new CYP3A4 variants as determinants of tacrolimus dose requirements in renal-transplanted patients.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Pharmacogenetics & Genomics

• Publication date

  2013-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/FPC.0b013e3283636856PMID 23778326
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmacogenetics of tacrolimus after renal transplantation: analysis of polymorphisms in genes encoding 16 drug metabolizing enzymes

  2011cited by this paper
• Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs

  2011cited by this paper
• A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients.

  2011cited by this paper
• Optimization of Initial Tacrolimus Dose Using Pharmacogenetic Testing

  2010cited by this paper
• Immunotherapy in Elderly Transplant Recipients

  2009cited by this paper
• Therapeutic monitoring of calcineurin inhibitors for the nephrologist.

  2007cited by this paper
• CYP3A5 and ABCB1 Polymorphisms and Tacrolimus Pharmacokinetics in Renal Transplant Candidates: Guidelines from an Experimental Study

  2006cited by this paper
• EFFECT OF CYP3A5 POLYMORPHISM ON TACROLIMUS METABOLIC CLEARANCE IN VITRO

  2006cited by this paper
• Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus.

  2005cited by this paper
• Tacrolimus dose requirement in renal transplant recipients is significantly higher when used in combination with corticosteroids.

  2003cited by this paper
• Increase in tacrolimus trough levels after steroid withdrawal

  2003cited by this paper
• Increased transcriptional activity of the CYP3A4*1B promoter variant

  2003cited by this paper
• Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5'-upstream regulatory region.

  1999cited by this paper

• Genetic Variation in ABCB1, ADRB1, CYP3A4, CYP3A5, NEDD4L and NR3C2 Confers Differential Susceptibility to Resistant Hypertension among South Africans

  2024cites this paper
• Effects of CYP3A4*22 and POR*28 variations on the pharmacokinetics of tacrolimus in renal transplant recipients: a meta-analysis of 18 observational studies

  2024cites this paper
• Signatures of Co-evolution and Co-regulation in the CYP3A and CYP4F Genes in Humans

  2023cites this paper
• Effects of CYP3A4*22 polymorphism on trough concentration of tacrolimus in kidney transplantation: a systematic review and meta-analysis

  2023influential citation
• Pharmacogenetics of Drug Metabolism: The Role of Gene Polymorphism in the Regulation of Doxorubicin Safety and Efficacy

  2022cites this paper
• Influence of CYP3A4*22 and CYP3A5*3 combined genotypes on tacrolimus dose requirements in Egyptian renal transplant patients

  2022cites this paper
• The effect of CYP3A4 genetic polymorphisms on the pharmacokinetics of calcineurin inhibitors in renal transplant recipients: a systematic review and meta-analysis protocol

  2021cites this paper
• Impact of pharmacogenetics on intravenous tacrolimus exposure and conversions to oral therapy.

  2021cites this paper
• CYP3A4∗22 Genotyping in Clinical Practice: Ready for Implementation?

  2021cites this paper
• A Machine Learning-Based Identification of Genes Affecting the Pharmacokinetics of Tacrolimus Using the DMETTM Plus Platform

  2020cites this paper
• Significance of ethnic factors in immunosuppressive therapy management after organ transplantation.

  2020cites this paper
• Using a pharmacogenetic clinical decision support system to improve psychopharmacotherapy dosing in patients with affective disorders

  2020cites this paper
• Effect of the Most Relevant CYP3A4 and CYP3A5 Polymorphisms on the Pharmacokinetic Parameters of 10 CYP3A Substrates

  2020cites this paper
• Influence of Genetic Variants on Steady-State Etonogestrel Concentrations Among Contraceptive Implant Users.

  2019cites this paper
• Defining screening panel of functional variants of CYP1A1, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 genes in Serbian population

  2019cites this paper
• Caveolin-1 in renal disease

  2018influential citation
• Genetic polymorphisms of cytochrome P450 enzymes: CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5 in the Croatian population

  2017cites this paper
• Individualization of the Immunosuppressive Therapy in Patients of Renal Transplantations through Pharmacodynamic and Pharmacogenetic Biomarkers

  2017cites this paper
• Blood DNA methylation pattern is altered in mesial temporal lobe epilepsy

  2017cites this paper
• Differences in genetic variants in lopinavir disposition among HIV-infected Bantu Africans.

  2016cites this paper
• Relationships of Selected CYP and ABCB1 Single Nucleotide Polymorphisms and Patient Characteristics with the Pharmacokinetics of Twice Daily Tacrolimus and Advagraf® in Renal Transplant Recipients

  2016cites this paper
• Effects of Genetic Polymorphism in CYP3A4 and CYP3A5 Genes on Tacrolimus Dose Among Kidney Transplant Recipients.

  2016cites this paper
• CYP3A pharmacogenetics and tacrolimus disposition in adult heart transplant recipients

  2016cites this paper
• Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing

  2015cites this paper
• Effects of the CYP3A4*1B Genetic Polymorphism on the Pharmacokinetics of Tacrolimus in Adult Renal Transplant Recipients: A Meta-Analysis

  2015cites this paper
• Pharmacogenetics and drug-induced nephrotoxicity in renal transplant recipients

  2015cites this paper
• The donor ABCB1 (MDR-1) C3435T polymorphism is a determinant of the graft glomerular filtration rate among tacrolimus treated kidney transplanted patients

  2015cites this paper
• ABCB1 (MDR-1) pharmacogenetics of tacrolimus in renal transplanted patients: a Next Generation Sequencing approach

  2015cites this paper
• Pregnane X receptor and hepatocyte nuclear factor 4&agr; polymorphisms are cooperatively associated with carbamazepine autoinduction

  2014cites this paper
• Clinical and genetic determinants of tacrolimus pharmacokinetics and pharmacodynamics in the transplant population

  2014cites this paper
• Cytochrome P450 pharmacogenetics : implications for anticancer and warfarin therapy

  2014cites this paper
• Role of pharmacogenomics in dialysis and transplantation

  2014cites this paper
• Impact of PPARA and POR polymorphisms on tacrolimus pharmacokinetics and new-onset diabetes in kidney transplant recipients.

  2014cites this paper
• Functional Gene Variants of CYP3A4

  2014cites this paper
• The Role of Pharmacogenetics in the Disposition of and Response to Tacrolimus in Solid Organ Transplantation

  2014cites this paper
• [Pharmacogenetics of tacrolimus: from bench to bedside?].

  2014cites this paper
• Genetic polymorphisms and kidney transplant outcomes

  2014cites this paper
• CYP3A5 and CYP3A4, but not ABCB1 polymorphisms affect tacrolimus dose-adjusted trough concentrations in kidney transplant recipients.

  2014cites this paper
• Combined effects of CYP3A5*1, POR*28, and CYP3A4*22 single nucleotide polymorphisms on early concentration-controlled tacrolimus exposure in de-novo renal recipients

  2014cites this paper
• Pharmacogenetics and immunosuppressive drugs

  2014cites this paper
• The CYP3A4*22 C>T single nucleotide polymorphism is associated with reduced midazolam and tacrolimus clearance in stable renal allograft recipients

  2014cites this paper